Keros Therapeutics (NASDAQ:KROS) Announces Earnings Results

Keros Therapeutics (NASDAQ:KROS) issued its quarterly earnings results on Wednesday. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13), Briefing.com reports. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. The company had revenue of $0.39 million during the quarter. During the same period in the previous year, the business posted ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% on a year-over-year basis.

Keros Therapeutics Price Performance

Keros Therapeutics stock traded up $0.69 during mid-day trading on Thursday, reaching $67.14. 280,507 shares of the company were exchanged, compared to its average volume of 368,850. The company has a fifty day simple moving average of $57.30 and a 200-day simple moving average of $51.99. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00. The firm has a market cap of $2.52 billion, a PE ratio of -13.09 and a beta of 1.23.

Insider Buying and Selling at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 22.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Scotiabank began coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday. Bank of America dropped their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Cantor Fitzgerald began coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating for the company. Finally, Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research report on Tuesday. They set a “buy” rating for the company. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $88.89.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.